Clowse, M. E. B., Scheuerle, A. E., Chambers, C., Afzali, A., Kimball, A., Cush, J. J., … Förger, F. (2018). OP0200 Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database. In Annals of the Rheumatic Diseases (Vol. 77, pp. 149–149). Elsevier BV. https://doi.org/10.1136/annrheumdis-2018-eular.2417

Clowse, M. E. B., A. E. Scheuerle, C. Chambers, A. Afzali, A. Kimball, J. J. Cush, M. Cooney, L. Shaughnessy, M. Vanderkelen, and F. Förger. “OP0200 Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database.” In Annals of the Rheumatic Diseases, 77:149–149. Elsevier BV, 2018. https://doi.org/10.1136/annrheumdis-2018-eular.2417.

Clowse MEB, Scheuerle AE, Chambers C, Afzali A, Kimball A, Cush JJ, et al. OP0200 Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database. In: Annals of the Rheumatic Diseases. Elsevier BV; 2018. p. 149–149.

Clowse, M. E. B., et al. “OP0200 Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database.” Annals of the Rheumatic Diseases, vol. 77, Elsevier BV, 2018, pp. 149–149. Crossref, doi:10.1136/annrheumdis-2018-eular.2417.

Clowse MEB, Scheuerle AE, Chambers C, Afzali A, Kimball A, Cush JJ, Cooney M, Shaughnessy L, Vanderkelen M, Förger F. OP0200 Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database. Annals of the Rheumatic Diseases. Elsevier BV; 2018. p. 149–149.